Management of High-Grade (Poorly Differentiated) Endometrial Stromal Sarcoma
For high-grade endometrial stromal sarcoma, perform total abdominal hysterectomy with bilateral salpingo-oophorectomy as the primary treatment, followed by consideration of adjuvant chemotherapy using a uterine leiomyosarcoma paradigm, as these aggressive tumors do not express hormone receptors and carry a poor prognosis with median overall survival of 16.5-53 months. 1, 2
Understanding the Disease Biology
High-grade endometrial stromal sarcoma (HG-ESS) represents a fundamentally different entity from low-grade ESS, despite the similar nomenclature:
- HG-ESS is characterized by small cells with high-grade cytology, frequent necrosis, and brisk mitotic activity (>10 mitoses per 10 HPF) 1
- These tumors do NOT express estrogen or progesterone receptors, unlike low-grade ESS, making hormonal therapy ineffective 2
- Median overall survival ranges from 16.5 to 53 months, representing an intermediate prognosis between low-grade ESS (excellent survival) and undifferentiated uterine sarcoma (poorest prognosis) 1
- Only 39% of patients present with uterine/cervix-confined disease, compared to 68% for low-grade ESS 1
Primary Surgical Management
Total abdominal hysterectomy (TAH) is the cornerstone of treatment for HG-ESS 2, 3:
- Bilateral salpingo-oophorectomy (BSO) should be performed if there is macroscopic ovarian involvement 3
- Avoid morcellation—perform en bloc intact resection to prevent tumor dissemination 4, 5
- Routine lymphadenectomy is NOT indicated, as lymph node involvement occurs in less than 5% of uterine sarcomas 6, 3
- Complete surgical resection with no residual disease is critical, as the presence of residual tumor after resection significantly worsens survival in high-grade ESS 1
Adjuvant Therapy Considerations
Chemotherapy
Systemic chemotherapy following a uterine leiomyosarcoma treatment paradigm is recommended for HG-ESS 2, 3:
- Gemcitabine-docetaxel followed by doxorubicin is an established regimen 6
- Doxorubicin/ifosfamide combination has demonstrated partial response in aggressive cases 7
- Trabectedin has some supporting evidence for use in high-grade uterine sarcomas 2, 6
Radiation Therapy
Adjuvant pelvic radiotherapy has NOT been shown to improve survival and is not routinely indicated for FIGO stage I-II disease 2, 6, 3:
- However, radiotherapy may be considered for selected high-risk cases, particularly those with sarcomatous overgrowth or adverse pathologic features 6
- The role remains uncertain given limited data in this rare tumor 2
Hormonal Therapy
Do NOT use hormonal therapy for HG-ESS, as these tumors lack hormone receptor expression, unlike low-grade ESS 2, 3
Management of Advanced or Recurrent Disease
For patients presenting with advanced-stage (III-IV) or recurrent HG-ESS:
- Surgical cytoreduction should be attempted when feasible, as complete resection impacts survival 1, 4
- Neoadjuvant or adjuvant chemotherapy using soft tissue sarcoma protocols (gemcitabine-docetaxel, doxorubicin-based regimens) 2, 4
- Consider pazopanib for stable disease after chemotherapy failure 7
- Biological agents and immunotherapy are under investigation but not yet standard 4
Surveillance Protocol
Follow patients with HG-ESS intensively given the aggressive nature 2:
- Every 3-4 months for the first 2-3 years 3
- Then every 6 months through year 5 3
- Annually thereafter 3
- Regular chest imaging is essential to detect pulmonary metastases, which are common in high-grade sarcomas 2
Critical Pitfalls to Avoid
Do NOT confuse HG-ESS with low-grade ESS—they require completely different treatment approaches. Low-grade ESS responds to hormonal therapy; high-grade does not 1, 2
Do NOT use tamoxifen, as it may have pro-estrogenic effects even in hormone receptor-negative tumors 2, 3
Do NOT perform morcellation during hysterectomy, as this can disseminate tumor cells and worsen prognosis 4, 5
Do NOT withhold chemotherapy based on early stage alone—HG-ESS behaves aggressively regardless of initial stage 1
Do NOT treat at non-specialized centers—referral to sarcoma centers with multidisciplinary expertise is strongly recommended given the rarity and complexity of these tumors 2, 6
Prognostic Factors
Key factors that influence outcomes in HG-ESS:
- Presence of residual disease after surgery is the most significant negative prognostic factor 1
- Stage at presentation—only 39% present with confined disease 1
- Molecular alterations such as CDKN2A homozygous deletion may confer particularly poor prognosis 7
- Tumor size, mitotic activity, and vascular invasion also impact survival 1